Loading patent…
AssigneeVion Pharmaceuticals, Inc.
InventorsDavid G. Bermudes, Ivan C. King, Caroline A. Clairmont, Michael Belcourt
Estimating the term…
The present application discloses the preparation and use of attenuated tumor-targeted bacteria vectors for the delivery of one or more primary effector molecule(s) to the site of a solid tumor. The primary effector molecule(s) of the invention is used in the methods of the invention to treat a solid tumor cancer such as a carcinoma, melanoma, lymphoma, or sarcoma. The invention relates to the surprising discovery that effector molecules, which may be toxic when administered systemically to a host, can be delivered locally to tumors by attenuated tumor-targeted bacteria with reduced toxicity to the host. The application also discloses to the delivery of one or more optional effector molecule(s) (termed secondary effector molecules) which may be delivered by the attenuated tumor-targeted bacteria in conjunction with the primary effector molecule(s).
An attenuated tumor-targeted bacteria comprising one or more nucleic acid molecules encoding one or more primary effector molecules, wherein each of the nucleic acid molecules is operably linked to a promoter, and at least one primary effector molecule is a mammalian anti-angiogenic polypeptide, and wherein said attenuated tumor-targeted bacteria is a Salmonella msbB− mutant lacking the ability to produce toxic lipopolysaccharide (LPS).
An attenuated tumor-targeted bacteria comprising,
Dependencies are inferred from the claim text.